Estimates of the total number of men with a previous diagnosis of prostate cancer in Italy range from 55,000 to 135,000. This wide range of variation is largely due to uncertainties on the number of protein-specific antigen-detected, asymptomatic cases. The number of clinically detected cases, including cases with advanced disease, is less subject to uncertainty, with reasonable estimates ranging from 45,000 to 60,000.
NegriE.La VecchiaC.DecarliA.: Cancer mortality in Italy, 1997: quantifying the fall in rates in women and men.Tumori, 87: 290–298, 2001.
2.
NegriE.La VecchiaC.DecarliA.: Cancer mortality in Italy, 1998.Tumori, 88: 89–94, 2002.
3.
LeviF.La VecchiaC.BoyleP.: The rise and fall of prostate cancer.Eur J Cancer Prev, 9: 381–385, 2000.
4.
PensonD.F.AlbertsenP.C.NelsonP.S.BarryM.StanfordJ.L.: Determining cause of death in prostate cancer: are death certificates valid?J Natl Cancer Inst, 93: 1822–1823, 2001.
5.
LeviF.La VecchiaC.RandimbisonL.ErlerG.TeV.C.FranceschiS.: Incidence, mortality and survival from prostate cancer in Vaud and Neuchatel, Switzerland, 1974–1994.Ann Oncol, 9: 31–35, 1998.
6.
FeinsteinA.R.SosinD.M.WellsC.K.: The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.N Engl J Med, 312: 1604–1608, 1985.
7.
LeviF.LucchiniF.BoyleP.NegriE.La VecchiaC.: Cancer incidence and mortality in Europe, 1988–92.J Epidemiol Biostat, 3: 295–373, 1998.
8.
BrayF.SankilaR.FerlayJ.ParkinD.M.: Estimates of cancer incidence and mortality in Europe in 1995.Eur J Cancer, 38: 99–166, 2002.
9.
PostP.N.DamhuisR.A.M.van der MeydenA.P.M. EUROCARE Working Group: Variation in survival of patients with prostate cancer in Europe since 1978.Eur J Cancer, 34: 2226–2231, 1998.
10.
LeviF.RandimbisonL.TeV.C.FranceschiS.La VecchiaC.: Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993.Ann Oncol, 11: 957–963, 2000.
11.
PisaniP.BrayF.ParkinM.: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population.Int J Cancer, 97: 72–81, 2002.
12.
MicheliA.FrancisciS.KroghV.RossiA.G.CrosignaniP. and the ITAPREVAL Working Group: Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study.Tumori, 85: 309–369, 1999.
13.
DearnaleyD.P.: Current issues in cancer: cancer of the prostate.BMJ, 308: 780–784, 1994.
14.
HullG.W.RabbaniF.AbbasF.WheelerT.M.KattanM.W.ScardinoP.T.: Cancer control with radical prostatectomy alone in 1,000 consecutive patients.J Urol, 167: 528–534, 2002.
15.
JohanssonJ-E, HolmbergL.JohanssonS.BergstromR.AdamiH.O.: Fifteen-year survival in prostate cancer. A prospective, population based study in Sweden.JAMA, 277: 467–471, 1997.
16.
ColonnaM.HedelinG.EsteveJ.GrosclaudeP.LaunoyG.BuemiA.ArveuxP.TretarreB.ChaplainG.Lesec'hJ.M.RaverdyN.CarliP.M.MenegozF.FaivreJ.: National cancer prevalence estimation in France.Int J Cancer, 87: 301–304, 2000.
17.
BoyleP.: Prostate cancer: creation and control of an epidemic.J Epidemiol Biostat, 1: 65–67, 1996.
18.
HsingA.W.TsaoL.DevesaS.: International trends and patterns of prostate cancer incidence and mortality.Int J Cancer, 85: 60–67, 2000.
19.
HankeyB.F.FeuerE.J.CleggL.X.HayesR.B.LeglerJ.M.ProrokP.C.RiesL.A.MerrillR.M.KaplanR.S.: Cancer surveillance series: interpreting trends in prostate cancer. Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.J Natl Cancer Inst, 91: 1017–1024, 1999.
20.
MerrillR.M.BrawleyO.W.: Prostate cancer incidence and mortality rates among white and black men.Epidemiology, 8: 117–120, 1997.
21.
MerrillR.M.: Partitioned prostate cancer prevalence estimates: an information measure of the disease burden.J Epidemiol Coram Health, 55: 191–197, 2001.
22.
De KoningH.J.AuvinenA.Berenguer SanchezA.Calais da SilvaF.CiattoS.DenisL.GohaganJ.K.HakamaM.HugossonJ.KranseR.NelenV.ProrokP.C.SchroderF.H.for the ERSPC and the PLCO Trials (the International Prostate Cancer Screening Trials Evaluation Group): Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostage cancer trial and the prostate, lung, colorectal and ovary cancer trial.Int J Cancer, 97: 237–244, 2002.
23.
EmiliozziP.LonghiS.ScarponeP.PansodoroA.DePaulaF.PansadoroV.: The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen.J Urol, 166: 845–850, 2001.
24.
ChanT.Y.ChanD.Y.RayK.L.StuzmanE.EpsteinJ.I.: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?J Urol, 166: 2181–84, 2001.
25.
DjavanB.RaveryV.ZlottaA.DobronskiP.DobronskiM.FakhariM.SeitzC.SusaniM.BorkowskiA.Boccon-GibodL.SchulmanC.C.MarbergerM.: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?J Urol, 166: 1679–1683, 2001.
26.
RiesL.A.EisnerM.P.KosaryC.L.HankeyB.F.MillerB.A.CleggL.EdwardsB.K. (Eds): SEER Cancer Statistics Review, 1973–1997.National Cancer Institute, Bethesda, MD, 2000.
27.
HewittM.BreenN.DevesaS.: Cancer prevalence and survivorship issues: analyses of the 1992 National Health Interview Survey.J Natl Cancer Inst, 91: 1480–1486, 1999.
